JP2024029009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024029009A5 JP2024029009A5 JP2023212944A JP2023212944A JP2024029009A5 JP 2024029009 A5 JP2024029009 A5 JP 2024029009A5 JP 2023212944 A JP2023212944 A JP 2023212944A JP 2023212944 A JP2023212944 A JP 2023212944A JP 2024029009 A5 JP2024029009 A5 JP 2024029009A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- small cell
- lung cancer
- mdm2 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165111.0 | 2017-04-05 | ||
| EP17165111 | 2017-04-05 | ||
| EP17197930.5 | 2017-10-24 | ||
| EP17197930 | 2017-10-24 | ||
| PCT/EP2018/058562 WO2018185135A1 (en) | 2017-04-05 | 2018-04-04 | Anticancer combination therapy |
| JP2019554792A JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Division JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024029009A JP2024029009A (ja) | 2024-03-05 |
| JP2024029009A5 true JP2024029009A5 (https=) | 2024-03-25 |
Family
ID=61899297
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Ceased JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
| JP2023212944A Pending JP2024029009A (ja) | 2017-04-05 | 2023-12-18 | 抗がん併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Ceased JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200101079A1 (https=) |
| EP (2) | EP4368200A3 (https=) |
| JP (2) | JP2020516604A (https=) |
| KR (2) | KR20240090927A (https=) |
| CN (2) | CN114949228A (https=) |
| AU (1) | AU2018248586A1 (https=) |
| BR (1) | BR112019021032A2 (https=) |
| CA (1) | CA3057558A1 (https=) |
| CL (2) | CL2019002800A1 (https=) |
| MX (1) | MX2019011945A (https=) |
| PH (1) | PH12019502291A1 (https=) |
| WO (1) | WO2018185135A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| NZ739090A (en) | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| TWI791794B (zh) * | 2018-03-20 | 2023-02-11 | 瑞士商諾華公司 | 藥物組合 |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US12268665B2 (en) * | 2018-08-08 | 2025-04-08 | Ascentage Pharma (Suzhou) Co., Ltd | Combination of immunotherapies with MDM2 inhibitors |
| EP4603098A3 (en) * | 2018-11-01 | 2025-09-03 | Alpha Tau Medical Ltd. | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen |
| EP3927344A4 (en) * | 2018-12-11 | 2023-01-18 | Kartos Therapeutics | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN EYE CONDITION |
| US20230058171A1 (en) | 2021-08-09 | 2023-02-23 | Boehringer Ingelheim International Gmbh | New oral pharmaceutical composition for cancer therapy |
| CN115089585A (zh) * | 2022-08-05 | 2022-09-23 | 中国科学院大学宁波华美医院 | Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用 |
| EP4638459A1 (en) * | 2022-12-22 | 2025-10-29 | Boehringer Ingelheim International GmbH | Crystalline form of an mdm2-p53 inhibitor and pharmaceutical compositions |
| EP4709384A2 (en) * | 2023-05-12 | 2026-03-18 | PMV Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| CA2682483A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| WO2010089411A2 (en) * | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| SG11201601763SA (en) | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| JP6577958B2 (ja) | 2014-04-11 | 2019-09-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用 |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| CA2956129C (en) | 2014-08-21 | 2022-10-25 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| WO2016100882A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| DK3317301T3 (da) * | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| PL3359542T3 (pl) * | 2015-10-09 | 2021-09-20 | Boehringer Ingelheim International Gmbh | Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53 |
| AU2017266298B2 (en) * | 2016-05-18 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti PD-1 and anti-LAG3 antibodies for cancer treatment |
| US20200239559A1 (en) * | 2017-09-29 | 2020-07-30 | Boehringer Ingelheim International Gmbh | Anti igf, anti pd-1, anti-cancer combination therapy |
-
2018
- 2018-04-04 EP EP24157330.2A patent/EP4368200A3/en not_active Withdrawn
- 2018-04-04 AU AU2018248586A patent/AU2018248586A1/en not_active Abandoned
- 2018-04-04 EP EP18715685.6A patent/EP3606556A1/en not_active Withdrawn
- 2018-04-04 CN CN202210548008.6A patent/CN114949228A/zh active Pending
- 2018-04-04 US US16/500,572 patent/US20200101079A1/en not_active Abandoned
- 2018-04-04 CN CN201880023850.XA patent/CN110505884B/zh not_active Expired - Fee Related
- 2018-04-04 KR KR1020247017327A patent/KR20240090927A/ko active Pending
- 2018-04-04 CA CA3057558A patent/CA3057558A1/en active Pending
- 2018-04-04 MX MX2019011945A patent/MX2019011945A/es unknown
- 2018-04-04 WO PCT/EP2018/058562 patent/WO2018185135A1/en not_active Ceased
- 2018-04-04 KR KR1020197032689A patent/KR20190132687A/ko not_active Ceased
- 2018-04-04 BR BR112019021032-6A patent/BR112019021032A2/pt unknown
- 2018-04-04 JP JP2019554792A patent/JP2020516604A/ja not_active Ceased
-
2019
- 2019-10-01 CL CL2019002800A patent/CL2019002800A1/es unknown
- 2019-10-04 PH PH12019502291A patent/PH12019502291A1/en unknown
-
2022
- 2022-07-15 US US17/812,735 patent/US20230025452A1/en not_active Abandoned
-
2023
- 2023-10-02 CL CL2023002946A patent/CL2023002946A1/es unknown
- 2023-12-18 JP JP2023212944A patent/JP2024029009A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024029009A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2021155426A5 (https=) | ||
| JP6761852B2 (ja) | がん治療 | |
| JP2024133474A5 (https=) | ||
| WO2010081817A1 (en) | Method for treating colorectal cancer | |
| JP2020502261A5 (https=) | ||
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| JP2021526138A5 (https=) | ||
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
| EA006295B1 (ru) | Применение производных дистамицина для противоопухолевой терапии | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2020535180A5 (https=) | ||
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JPWO2020030977A5 (https=) | ||
| JPWO2019226685A5 (https=) | ||
| CN1302777C (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 | |
| US10080761B2 (en) | Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2 | |
| US20240173323A1 (en) | Combination therapy for cancer treatment | |
| Eswaran et al. | Concurrent chemoradiation with nano-paclitaxel and carboplatin in locally advanced cervical cancer: A study at quaternary care medical center | |
| JPWO2021262562A5 (https=) | ||
| Olimova | Neoadjuvant chemotherapy in locally advanced cervical cancer: Two randomized studies | |
| Akhmedov et al. | Neoadjuvant intraarterial chemotherapy and chemoembolization in locally advanced cervix cancer |